Catapres and Ventricular hypertrophy - a phase IV clinical study of FDA data

Summary:

Ventricular hypertrophy is reported as a side effect among people who take Catapres (clonidine hydrochloride), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Vioxx, and have Arthritis.

The phase IV clinical study analyzes which people have Ventricular hypertrophy when taking Catapres. It is created by eHealthMe based on reports of 6,532 people who have side effects when taking Catapres from the FDA, and is updated regularly.

What is Catapres?

Catapres has active ingredients of clonidine hydrochloride. It is often used in high blood pressure. eHealthMe is studying from 6,680 Catapres users. Check the latest studies of Catapres.

What is Ventricular hypertrophy?

Ventricular hypertrophy (enlargement of ventricles (lower chambers) in the heart) is found to be associated with 695 drugs and 794 conditions by eHealthMe. Check the latest studies of Ventricular hypertrophy.

On Aug, 11, 2026

6,532 people reported to have side effects when taking Catapres.
Among them, 22 people (0.34%) have Ventricular hypertrophy.

Could Catapres cause Ventricular hypertrophy?

Among these 22 people:

How long have people been on Catapres when they have Ventricular hypertrophy? *

What is the gender of people who have Ventricular hypertrophy when taking Catapres? *

female: 63.64 %
male: 36.36 %

What is the age of people who have Ventricular hypertrophy when taking Catapres? *

What are other drugs people take besides Catapres? *

What are other side effects people have besides Ventricular hypertrophy? *

Mitral Valve Incompetence (inefficient heart valve): 10 people, 45.45%
Tricuspid Valve Incompetence (inefficient heart valve): 9 people, 40.91%
Cardiac Failure Congestive: 8 people, 36.36%
Nausea (feeling of having an urge to vomit): 6 people, 27.27%
Chest Pain: 6 people, 27.27%
Malaise (a feeling of general discomfort or uneasiness): 5 people, 22.73%
Weakness: 5 people, 22.73%
Gait Abnormal: 4 people, 18.18%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 4 people, 18.18%
Oedema Peripheral (superficial swelling): 4 people, 18.18%

What are the existing conditions these people have? *

Arthritis (form of joint disorder that involves inflammation of one or more joints): 3 people, 13.64%
Anaemia (lack of blood): 2 people, 9.09%
Weight Loss: 1 person, 4.55%
Osteoporosis (bones weak and more likely to break): 1 person, 4.55%
Intervertebral Disc Degeneration (spinal disc degeneration): 1 person, 4.55%
Hyperphosphataemia (electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood): 1 person, 4.55%
Gout (uric acid crystals building up in the body): 1 person, 4.55%
Enlarged Heart: 1 person, 4.55%

* Approximation only. Some reports may have incomplete information.

Do you take Catapres and have Ventricular hypertrophy?

- Check whether Ventricular hypertrophy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Catapres:

Catapres (6,680 reports)

Browse all side effects of Catapres:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Ventricular hypertrophy:

Ventricular hypertrophy (695 drugs)

Browse all the conditions that are associated with Ventricular hypertrophy:

Ventricular hypertrophy (794 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on clonidine hydrochloride (the active ingredients of Catapres) and Catapres (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.